Director/PDMR Shareholding

RNS Number : 1276D

Instem plc

29 January 2018

 

Instem plc
("Instem" or the "Company")

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, was notified on 25 January 2018, that the DG 2008 Discretionary Settlement (of which David Gare (the Company chairman) and his wife are the trustees) transferred 70,000 ordinary shares of 10p each in the Company ("Ordinary Shares") to David's son Adrian Gare and a further 70,000 to his daughter, Deborah Walker, for nil consideration. Following the transaction, the DG 2008 Discretionary Settlement now has a total interest in 1,258,427 Ordinary Shares, representing 7.92% of the Company's issued share capital.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	David Gare and his wife (via the DG 2008 Discretionary Settlement)
2	Reason for the notification
a)	Position/status	Chairman of the Company
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Instem plc
b)	LEI	213800PILYUFNNROQX68
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 10p each
	Identification code	GB00B3TQCK30
b)	Nature of the transaction	Transfer of ordinary shares
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			0p	140,000
d)	Aggregated information
	- Aggregated volume	N/A
	- Price
e)	Date of the transaction	25 January 2018
f)	Place of the transaction	London Stock Exchange (XLON)

For further information, please contact:

Instem plc	[phone]
Phil Reason, CEO
Nigel Goldsmith, CFO
N+1 Singer (Nominated Adviser & Broker)	[phone]
Richard Lindley James White
Walbrook Financial PR	[phone]
Paul Cornelius	[e-mail]
Helen Cresswell Sam Allen

About Instem 

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

 Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

To learn more about Instem solutions and its mission, please visit instem.com.

 

END

 

 

DSHBCGDBXUDBGII